Teva’s commercial advantage from being the sole rituximab biosimilar sponsor with a rheumatoid arthritis indication has been blunted. Amgen’s Riabni (rituximab-arrx) has been approved for the same inflammatory joint disease indication by the US Food and Drug Administration.
Amgen Rivals Teva With Rituximab Approved For RA
US Market Composed Of Three Biosimilars Plus Rituxan
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
